Methicillin Sodium Salt (C3238): Mechanistic and Benchmarking Guide

Executive Summary: Methicillin sodium salt (CAS 132-92-3) is a semi-synthetic, penicillinase-resistant β-lactam antibiotic primarily used to inhibit the transpeptidase activity of penicillin-binding proteins (PBPs) in Staphylococcus aureus and related gram-positive bacteria [APExBIO]. It is highly effective against methicillin-sensitive S. aureus (MSSA), with minimum inhibitory concentrations (MIC) ranging from 0.125 to 2 μg/mL under standard laboratory conditions (broth/agar dilution, 37°C, pH 7.2) [Lancet, 2025]. Resistance in methicillin-resistant S. aureus (MRSA) is mediated by the mecA gene encoding PBP2a, resulting in MIC values >8 μg/mL. Methicillin sodium salt is typically employed in susceptibility testing at 0.06–16 μg/mL and is soluble at ≥14.4 mg/mL in DMSO. Its clinical relevance has declined due to MRSA prevalence, but it remains a benchmark tool in research and diagnostics [Methicillin Sodium Salt in Translational Research].

Biological Rationale

Methicillin sodium salt is a pivotal agent in the study and management of gram-positive bacterial infections, especially those caused by Staphylococcus aureus. As a semi-synthetic penicillin antibiotic, it was developed to overcome the enzymatic degradation by penicillinase (β-lactamase) produced by certain staphylococcal strains [Advanced Strategies for Modeling]. It operates by inhibiting bacterial cell wall synthesis, specifically the cross-linking of peptidoglycan strands. This mode of action makes it highly relevant for both clinical and experimental contexts, particularly in resistance benchmarking and the elucidation of bacterial cell wall biosynthesis pathways. Methicillin sodium salt is also used as a reference standard in antibiotic susceptibility testing for MSSA and MRSA strains [Data-Driven Solution].

Mechanism of Action of Methicillin sodium salt

Methicillin sodium salt, a penicillin-binding protein inhibitor, exerts its bactericidal effect by binding covalently to PBPs, notably PBP1 and PBP2, at the active serine site. This inhibits the transpeptidase-catalyzed cross-linking of the peptidoglycan polymer chains, a critical step in bacterial cell wall synthesis. The result is cell lysis due to osmotic instability. MRSA strains evade this mechanism by expressing PBP2a, encoded by the mecA gene, which exhibits low affinity for methicillin and other β-lactam antibiotics, conferring resistance [Lancet, 2025]. Methicillin sodium salt is inactive against most gram-negative bacteria due to their outer membrane permeability barriers and intrinsic β-lactamase expression.

Evidence & Benchmarks

• Methicillin sodium salt exhibits an MIC of 0.125–2 μg/mL against MSSA in standardized broth or agar dilution assays at 37°C, pH 7.2 (see Table 2) (Lancet, 2025).
• MIC values for MRSA strains consistently exceed 8 μg/mL under identical conditions due to the presence of the mecA gene (Lancet, 2025).
• Laboratory use concentrations for susceptibility testing range from 0.06 to 16 μg/mL, with both agar and broth dilution methods being validated (APExBIO).
• Clinical intravenous dosing in adults is 4–12 g/day (divided into four doses), achieving plasma peaks of 10–40 μg/mL; pediatric dosing is 50–100 mg/kg/day (APExBIO).
• Methicillin sodium salt is soluble at ≥14.4 mg/mL in DMSO and must be stored at -20°C to maintain stability (APExBIO).
• Clinical utility has declined due to MRSA prevalence, but the compound remains a key research reagent and benchmarking standard (Methicillin Sodium Salt in Translational Research).

Applications, Limits & Misconceptions

Methicillin sodium salt is indicated primarily for laboratory susceptibility testing, benchmarking MSSA versus MRSA phenotypes, and modeling bacterial cell wall inhibition in gram-positive pathogens. It is used as a reference agent for the development of new antibiotics and for quality control in clinical microbiology laboratories.

• Skin and soft tissue infection models
• Sepsis and pneumonia infection research
• Antibiotic resistance mechanism elucidation
• Comparative benchmarking of penicillinase-resistant antibiotics

Common Pitfalls or Misconceptions

• Methicillin sodium salt is not effective against MRSA due to PBP2a-mediated resistance.
• It is not active against gram-negative bacteria owing to outer membrane exclusion and β-lactamase activity.
• Clinical use is obsolete in most settings due to the prevalence of MRSA; alternative agents are preferred.
• Solutions of methicillin sodium salt are unstable at room temperature and should not be stored long-term in solution.
• Allergic reactions can occur, including cross-reactivity with other β-lactams; patient history is critical in clinical use.

This article extends the quantitative workflow guidance found in Methicillin Sodium Salt (SKU C3238): Data-Driven Solution by providing updated benchmarks and clarifying the mechanistic basis for MRSA resistance. For further context on translational impact, see Methicillin (Sodium Salt) as a Precision Tool for Advancing Staphylococcal Research, which discusses broader gram-positive infection models.

Workflow Integration & Parameters

For laboratory usage, methicillin sodium salt (APExBIO C3238) is typically prepared as a stock solution at ≥14.4 mg/mL in DMSO, aliquoted, and stored at -20°C. Susceptibility testing is performed using standardized broth or agar dilution techniques at concentrations between 0.06 and 16 μg/mL. The compound should be thawed immediately prior to use, and unused solution should be discarded after single-use to avoid degradation. Quality control strains (MSSA ATCC 29213, MRSA ATCC 43300) are recommended for benchmarking. For detailed mechanistic and translational workflow guidance, see Methicillin Sodium Salt in Translational Research, which this article updates with current resistance benchmarks and optimized parameters.

Conclusion & Outlook

Methicillin sodium salt remains a cornerstone in antimicrobial susceptibility testing and resistance research, despite diminished clinical use due to MRSA prevalence. Its well-characterized mechanism and reproducibility make it indispensable for benchmarking and modeling S. aureus infections. APExBIO’s C3238 formulation offers validated purity and consistent performance for research applications. As new antibiotics such as gepotidacin are developed to address resistance, methicillin sodium salt will continue to serve as a critical reference standard in both basic and translational infectious disease research [Lancet, 2025].